table of content
1 Study Coverage
1.1 Opioids Agonist Drugs Product Introduction
1.2 Global Opioids Agonist Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Opioids Agonist Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Opioids Agonist Drugs Sales in Volume for the Year 2017-2028
1.3 United States Opioids Agonist Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Opioids Agonist Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Opioids Agonist Drugs Sales in Volume for the Year 2017-2028
1.4 Opioids Agonist Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Opioids Agonist Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Opioids Agonist Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Opioids Agonist Drugs Market Dynamics
1.5.1 Opioids Agonist Drugs Industry Trends
1.5.2 Opioids Agonist Drugs Market Drivers
1.5.3 Opioids Agonist Drugs Market Challenges
1.5.4 Opioids Agonist Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Opioids Agonist Drugs Market Segment by Type
2.1.1 Codeine
2.1.2 Fentanyl
2.1.3 Meperidine
2.1.4 Methadone
2.1.5 Morphine
2.1.6 Hydrocodone
2.2 Global Opioids Agonist Drugs Market Size by Type
2.2.1 Global Opioids Agonist Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Opioids Agonist Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Opioids Agonist Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Opioids Agonist Drugs Market Size by Type
2.3.1 United States Opioids Agonist Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Opioids Agonist Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Opioids Agonist Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Opioids Agonist Drugs Market Segment by Application
3.1.1 Pain Management
3.1.2 Cough Treatment
3.1.3 Diarrhea Treatment
3.2 Global Opioids Agonist Drugs Market Size by Application
3.2.1 Global Opioids Agonist Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Opioids Agonist Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Opioids Agonist Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Opioids Agonist Drugs Market Size by Application
3.3.1 United States Opioids Agonist Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Opioids Agonist Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Opioids Agonist Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Opioids Agonist Drugs Competitor Landscape by Company
4.1 Global Opioids Agonist Drugs Market Size by Company
4.1.1 Top Global Opioids Agonist Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Opioids Agonist Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Opioids Agonist Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Opioids Agonist Drugs Price by Manufacturer (2017-2022)
4.2 Global Opioids Agonist Drugs Concentration Ratio (CR)
4.2.1 Opioids Agonist Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Opioids Agonist Drugs in 2021
4.2.3 Global Opioids Agonist Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Opioids Agonist Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Opioids Agonist Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Opioids Agonist Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Opioids Agonist Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Opioids Agonist Drugs Market Size by Company
4.5.1 Top Opioids Agonist Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Opioids Agonist Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Opioids Agonist Drugs Sales by Players (2020, 2021 & 2022)
5 Global Opioids Agonist Drugs Market Size by Region
5.1 Global Opioids Agonist Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Opioids Agonist Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Opioids Agonist Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Opioids Agonist Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Opioids Agonist Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Opioids Agonist Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Opioids Agonist Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Opioids Agonist Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Opioids Agonist Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Opioids Agonist Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Opioids Agonist Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Opioids Agonist Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Opioids Agonist Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Opioids Agonist Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Opioids Agonist Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Opioids Agonist Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Opioids Agonist Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Purdue Pharma
7.1.1 Purdue Pharma Corporation Information
7.1.2 Purdue Pharma Description and Business Overview
7.1.3 Purdue Pharma Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Purdue Pharma Opioids Agonist Drugs Products Offered
7.1.5 Purdue Pharma Recent Development
7.2 Titan pharmaceuticals
7.2.1 Titan pharmaceuticals Corporation Information
7.2.2 Titan pharmaceuticals Description and Business Overview
7.2.3 Titan pharmaceuticals Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Titan pharmaceuticals Opioids Agonist Drugs Products Offered
7.2.5 Titan pharmaceuticals Recent Development
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim Corporation Information
7.3.2 Boehringer Ingelheim Description and Business Overview
7.3.3 Boehringer Ingelheim Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Boehringer Ingelheim Opioids Agonist Drugs Products Offered
7.3.5 Boehringer Ingelheim Recent Development
7.4 Janssen Pharmaceuticals, Inc
7.4.1 Janssen Pharmaceuticals, Inc Corporation Information
7.4.2 Janssen Pharmaceuticals, Inc Description and Business Overview
7.4.3 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Products Offered
7.4.5 Janssen Pharmaceuticals, Inc Recent Development
7.5 Sanofi
7.5.1 Sanofi Corporation Information
7.5.2 Sanofi Description and Business Overview
7.5.3 Sanofi Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Sanofi Opioids Agonist Drugs Products Offered
7.5.5 Sanofi Recent Development
7.6 Sun Pharmaceuticals
7.6.1 Sun Pharmaceuticals Corporation Information
7.6.2 Sun Pharmaceuticals Description and Business Overview
7.6.3 Sun Pharmaceuticals Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Sun Pharmaceuticals Opioids Agonist Drugs Products Offered
7.6.5 Sun Pharmaceuticals Recent Development
7.7 Mallinckrodt Pharmaceuticals
7.7.1 Mallinckrodt Pharmaceuticals Corporation Information
7.7.2 Mallinckrodt Pharmaceuticals Description and Business Overview
7.7.3 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Products Offered
7.7.5 Mallinckrodt Pharmaceuticals Recent Development
7.8 Egalet Corporation
7.8.1 Egalet Corporation Corporation Information
7.8.2 Egalet Corporation Description and Business Overview
7.8.3 Egalet Corporation Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Egalet Corporation Opioids Agonist Drugs Products Offered
7.8.5 Egalet Corporation Recent Development
7.9 Endo Pharmaceuticals Inc.
7.9.1 Endo Pharmaceuticals Inc. Corporation Information
7.9.2 Endo Pharmaceuticals Inc. Description and Business Overview
7.9.3 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Products Offered
7.9.5 Endo Pharmaceuticals Inc. Recent Development
7.10 Allergan, Plc
7.10.1 Allergan, Plc Corporation Information
7.10.2 Allergan, Plc Description and Business Overview
7.10.3 Allergan, Plc Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Allergan, Plc Opioids Agonist Drugs Products Offered
7.10.5 Allergan, Plc Recent Development
7.11 Pfizer Inc
7.11.1 Pfizer Inc Corporation Information
7.11.2 Pfizer Inc Description and Business Overview
7.11.3 Pfizer Inc Opioids Agonist Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Pfizer Inc Opioids Agonist Drugs Products Offered
7.11.5 Pfizer Inc Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Opioids Agonist Drugs Industry Chain Analysis
8.2 Opioids Agonist Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Opioids Agonist Drugs Distributors
8.3 Opioids Agonist Drugs Production Mode & Process
8.4 Opioids Agonist Drugs Sales and Marketing
8.4.1 Opioids Agonist Drugs Sales Channels
8.4.2 Opioids Agonist Drugs Distributors
8.5 Opioids Agonist Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
